Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | EA3163: chemo vs surgery + PORT for organ preservation in T3/T4 sinonasal SCC

Nabil Saba • 15 Sep 2024
ESMO 2024
Head and Neck Cancer
EA3163

Nabil Saba, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses results from the Phase II EA3163 trial (NCT03493425), which investigated neoadjuvant chemotherapy for structure preservation (SP) in patients with resectable nonparanasal sinus squamous cell carcinoma (NPNSCC) requiring orbital or skull base resection. The study compared standard surgery and postoperative radiotherapy (PORT) with or without neoadjuvant chemotherapy (docetaxel and cisplatin). While the trial closed early due to slow accrual, findings showed a trend toward improved SP rates in the chemotherapy group. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nabil Saba

ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
3:09
ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
Nabil Saba • 1 Jun 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026

Related Videos

Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
1:04
Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas • 31 May 2026
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals